UK markets close in 3 hours 44 minutes
  • FTSE 100

    -139.57 (-1.91%)
  • FTSE 250

    -454.82 (-2.39%)
  • AIM

    -15.32 (-1.71%)

    +0.0039 (+0.33%)

    -0.0025 (-0.21%)

    -895.25 (-5.38%)
  • CMC Crypto 200

    -31.96 (-7.27%)
  • S&P 500

    -2.72 (-0.07%)
  • DOW

    +82.32 (+0.27%)

    -0.71 (-0.65%)

    -8.10 (-0.45%)
  • NIKKEI 225

    -411.56 (-1.54%)

    -137.10 (-0.62%)
  • DAX

    -366.00 (-2.81%)
  • CAC 40

    -169.73 (-2.81%)

Alpha-1 Antitrypsin Deficiency Market Research Report 2022: Unmet Needs and Opportunities, Treatment Options, Pipeline Assessment, R&D Strategies, Outlook

·3-min read
Company Logo
Company Logo

Dublin, June 10, 2022 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to's offering.

The 2MM market (US and Germany) is expected to grow from $1.2 billion in 2021 to $3.48 billion in 2031 at a CAGR of 11.2%. The introduction of 4 new pipeline agents are key drivers of this market growth.

Alpha-1 antitrypsin deficiency (AATD) is an inherited disease that causes an increased risk of chronic obstructive pulmonary disorder (COPD), hepatic failure, skin problems (panniculitis), and inflammation of the blood vessels (vasculitis).

The current treatment options for AATD are alpha-1 proteinase inhibitor (A1-PI) therapies, which provide the alpha-1 antitrypsin (AAT) protein that prevents the overproduction of elastase in lung tissue.

Forecasts cover three time points: base year, 5-year, and 10-year

  • The prevalence of AATD is increasing at a steady rate, in line with population growth in the 2MM at an AGR of 1.07%

  • Currently, the treatment regimen for AATD in the 2MM is entirely limited to the four marketed alpha-1 proteinase inhibitors

  • There are several unmet needs in this space, including the need for early diagnosis of AATD and novel therapies with improved efficacy

  • The AATD late-stage R&D pipeline is focused on developing a novel AI-PI, NE inhibitor therapies, and RNAi therapies

  • Significant growth is expected throughout the forecast period as the AATD population steadily increases and novel therapies enter the market


  • Overview of AATD, including epidemiology, symptoms, diagnosis, and disease management

  • Annualized AATD therapeutics market revenue, annual cost of therapy and treatment usage pattern in 2021 and forecast for ten years to 2031

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AATD therapeutics market

  • Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for AATD treatment. The most promising candidates in late-stage development are profiled

  • Analysis of the current and future market competition in the global AATD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications

Key Topics Covered:

1 Executive Summary
1.1 Executive Summary

2 Disease Overview
2.1 Overview of Alpha-1 Antitrypsin Deficiency (AATD)
2.2 AATD SWOT Analysis
2.3 Classification of AATD

3 Epidemiology
3.1 Diagnosed Prevalent Cases of Alpha-1 Antitrypsin Deficiency, Men and Women, 2021-31
3.2 Sources and Methodology

4 Current Treatment Options
4.1 Treatment Paradigm
4.2 Marketed Products
4.3 Product Profiles: Alpha-1 Proteinase Inhibitors (Glassia, Prolastin-C, Zemaira/Respreeza, Aralast NP)

5 Unmet Needs and Opportunities
5.1 Unmet Needs in AATD
5.2 Earlier AATD Disease Diagnosis
5.3 AATD Treatments with Improved Efficacy
5.4 Reduced Cost for AATD Treatments
5.5 Treatment Dosage for AATD Patients
5.6 Patient Compliance

6 Pipeline Assessment
6.1 AATD Pipeline Overview
6.2 Leading Pipeline Agents
6.3 Product Profiles: Alpha-1 proteinase inhibitor (human) second generation, PHP-303, Alvelestat, Belcesiran, ARO-AAT (Fazirsiran Sodium)
6.4 Pipeline Products - Review Designations
6.5 AATD: Clinical Trials (Phase II/III) Overview

7 R&D Strategies
7.1 Trends in Clinical Trial Design in AATD
7.2 Trends in Deal-Making in AATD

8 Market Outlook
8.1 AATD Sales Forecast
8.2 AATD Market Forecast
8.3 Market Drivers and Barriers

9 Appendix

For more information about this drug pipelines report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting